Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Careers
Contact Us
United Kingdom
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Corporate Philosophy
Pharma Repurposed
Positions & Guidelines
Our people
Careers at Takeda UK
Graduate and Internship Programmes
Diversity, Equity & Inclusion at Takeda UK
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Our Products
Collaborative and Joint Working Projects
Combination Treatments
Delivering for patients with GI conditions
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Transparency Disclosures
EFPIA Disclosure Code Reports
Patient Group and Members of the Public Disclosures
Donations and Grants
Clinical Trials and Results
Legitimate Interests for Transparency Reporting
Careers
Contact Us
United Kingdom
HOME
Corporate Responsibility
Transparency Disclosures
Patient Group and Members of the Public Disclosures
Takeda UK 2023 Disclosures for Members of the Public including Patients and Journalists
Transparency Disclosures
EFPIA Disclosure Code Reports
Patient Group and Members of the Public Disclosures
Donations and Grants
Clinical Trials and Results
Legitimate Interests for Transparency Reporting
Takeda UK 2023 Disclosures for Members of the Public including Patients and Journalists
Takeda UK support provided to Members of the Public including Patients and Journalists during 2023:
Members of the Public
Number: 8
Fees:
1008 (Consultancy Services)
105 (Participating in a survey)
Patients
Number: 77
Fees:
8110.85 (Honoraria for speaking, consulting and advisory services)
810 (Participating in a survey)
Out of pocket expenses
5401.14 (Travel and accommodation expenses)
Journalists
Number: 0
EXA/GB/CORP/0279
Date of preparation: June 2024
TOP
Close